Molecularly Imprinted Polymers (MIPs) as Theranostic Systems for Sunitinib Controlled Release and Self-Monitoring in Cancer Therapy

Cytotoxic agents that are used conventionally in cancer therapy present limitations that affect their efficacy and safety profile, leading to serious adverse effects. In the aim to overcome these drawbacks, different approaches have been investigated and, among them, theranostics is attracting inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Ortensia Ilaria, Ruffo, Mariarosa, Malivindi, Rocco, Vattimo, Anna Francesca, Pezzi, Vincenzo, Puoci, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022407/
https://www.ncbi.nlm.nih.gov/pubmed/31947815
http://dx.doi.org/10.3390/pharmaceutics12010041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022407/
https://www.ncbi.nlm.nih.gov/pubmed/31947815
http://dx.doi.org/10.3390/pharmaceutics12010041

Ejemplares similares